Why the study?
Does streptozotocin-induced diabetes alter the pharmacological reactivity of conduit and resistance intrapulmonary arteries in a rat model?
Does streptozotocin-induced diabetes alter the pharmacological reactivity of conduit and resistance intrapulmonary arteries in a rat model?
In a rat model, chronic STZ-induced diabetes impairs the constrictor responsiveness of conduit pulmonary arteries but spares small resistance arteries, suggesting that diabetes-induced pulmonary hypertension is not driven by enhanced pulmonary vascular reactivity to these vasoconstrictors.
No takes yet. Share an insight, caveat, or question.
STZ diabetes blunts conduit pulmonary artery reactivity in rats; hypothesis-generating for mechanisms of diabetic pulmonary vasculopathy and requires human validation before any clinical inference.
Gurney et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: